Shunichiro Asahara

Dr. Shunichiro Asahara

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
TMToshiya Matsukawa
Toshiya Matsukawa
TYTakashi Yagi
Takashi Yagi
TUTohru Uchida
Tohru Uchida
MSMashito Sakai
Mashito Sakai
MMMasaru Mitsushima
Masaru Mitsushima
MMMichihiro Matsumoto
Michihiro Matsumoto
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes are interacting comorbidities of obesity, and increased hepatic de novo lipogenesis (DNL), driven by hyperinsulinemia and carbohydrate overload, contributes to their pathogenesis. Fatty acid synthase (FASN), a key enzyme of hepatic DNL, is upregulated in association with insulin resistance. However, the therapeutic potential of targeting FASN in hepatocytes for obesity-associated metabolic diseases is unknown. Here, we show that hepatic FASN deficiency differentially affects NAFLD and diabetes depending on the etiology of obesity. Hepatocyte-specific ablation of FASN ameliorated NAFLD and diabetes in melanocortin 4 receptor–deficient mice but not in mice with diet-induced obesity. In leptin-deficient mice, FASN ablation alleviated hepatic steatosis and improved glucose tolerance but exacerbated fed hyperglycemia and liver dysfunction. The beneficial effects of hepatic FASN deficiency on NAFLD and glucose metabolism were associated with suppression of DNL and attenuation of gluconeogenesis and fatty acid oxidation, respectively. The exacerbation of fed hyperglycemia by FASN ablation in leptin-deficient mice appeared attributable to impairment of hepatic glucose uptake triggered by glycogen accumulation and citrate-mediated inhibition of glycolysis. Further investigation of the therapeutic potential of hepatic FASN inhibition for NAFLD and diabetes in humans should thus consider the etiology of obesity.

21 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Shunichiro AsaharaShunichiro Asahara
Shunichiro Asahara
HIHiroyuki Inoue
Hiroyuki Inoue
HWHitoshi Watanabe
Hitoshi Watanabe
YKYoshiaki Kido
Yoshiaki Kido
Pancreatic β-cells are the only type of cells that can control glycemic levels via insulin secretion. Thus, to explore the mechanisms underlying pancreatic β-cell failure, many reports have clarified the roles of important molecules, such as the mechanistic target of rapamycin (mTOR), which is a central regulator of metabolic and nutrient cues. Studies have uncovered the roles of mTOR in the function of β-cells and the progression of diabetes, and they suggest that mTOR has both positive and negative effects on pancreatic β-cells in the development of diabetes.

1 March 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AKAyumi Kanno
Ayumi Kanno
Shunichiro AsaharaShunichiro Asahara
Shunichiro Asahara
KMKatsuhisa Masuda
Katsuhisa Masuda
TMTomokazu Matsuda
Tomokazu Matsuda
MKMaki Kimura-Koyanagi
Maki Kimura-Koyanagi
YKYoshiaki Kido
Yoshiaki Kido

12 December 2019 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
HIHiroyuki Inoue
Hiroyuki Inoue
MSMayumi Saito
Mayumi Saito
KKKumiko Kouchi
Kumiko Kouchi
Shunichiro AsaharaShunichiro Asahara
Shunichiro Asahara
FNFumihiko Nakamura
Fumihiko Nakamura
YKYoshiaki Kido
Yoshiaki Kido
Aims/Introduction: Mean platelet volume (MPV) is a widely used biological marker of platelet function and activity. Increased MPV is associated with accelerated thrombopoiesis and an elevated risk of cardiovascular disease. However, it is not known whether higher MPV is related to the pathogenesis of type 2 diabetes and diabetic macrovascular complications in Japanese patients. Therefore, we analyzed MPV and its correlation with atherosclerosis in Japanese patients with type 2 diabetes and those who had prediabetes.Materials and Methods: We divided the patients into three groups: normoglycemic patients (n = 56), prediabetes patients (n = 44) and type 2 diabetes patients group, (n = 115). We measured platelet parameters and evaluated arterial stiffness in the three groups.Results: Significantly higher MPV was found in the type 2 diabetes mellitus and prediabetes patients compared with normoglycemic patients. MPV was significantly correlated with fasting blood glucose and glycated hemoglobin levels. Multiple linear regression analysis showed that MPV was positively correlated with HbA1c, even after adjustment for confounding factors. In the evaluation of arterial stiffness by measuring the cardio‐ankle vascular index and maximum intima‐media thickness, MPV showed a positive correlation with these parameters.Conclusions: These findings suggest that MPV was significantly increased in the early stage of type 2 diabetes. We showed positive correlations between MPV and HbA1c levels, and between MPV and arterial stiffness in Japanese patients with type 2 diabetes.

17 September 2018 in Diabetology International
Verified
Journal Article
Open access
PDF file
Shunichiro AsaharaShunichiro Asahara
Shunichiro Asahara
WOWataru Ogawa
Wataru Ogawa

5 October 2018 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
AKAyumi Kanno
Ayumi Kanno
Shunichiro AsaharaShunichiro Asahara
Shunichiro Asahara
MKMao Kawamura
Mao Kawamura
AFAyuko Furubayashi
Ayuko Furubayashi
STShoko Tsuchiya
Shoko Tsuchiya
YKYoshiaki Kido
Yoshiaki Kido
Aims/Introduction: The preservation of pancreatic β‐cell mass is an essential factor in the onset and development of type 2 diabetes mellitus. Recently, sodium–glucose cotransporter 2 inhibitors have been launched as antihyperglycemic agents, and their organ‐protective effects are attracting attention. They are also reported to have favorable effects on the preservation of pancreatic β‐cell mass, but the appropriate timing for the administration of sodium–glucose cotransporter 2 inhibitors is obscure.Materials and Methods: In the present study, we administered a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, to an animal model of type 2 diabetes mellitus, db/db mice, and investigated the adequate timing and duration for its administration. We also carried out microarray analysis using pancreatic islets from db/db mice.Results: We found that dapagliflozin preserved pancreatic β‐cell mass depending on the duration of administration and markedly improved blood glucose levels. If the duration was the same, the earlier administration of dapagliflozin was more effective in preserving pancreatic β‐cell mass, increasing serum insulin levels and improving blood glucose levels. From microarray analysis, we discovered that the expression of Agr2, Tff2 and Gkn3 was significantly upregulated after the early administration of dapagliflozin. This upregulated gene expression might provide a legacy effect for the preservation of pancreatic β‐cell mass.Conclusions: We expect that the early administration of dapagliflozin would provide a long‐lasting effect in preserving pancreatic β‐cell mass.